Results: The mean age of the study patients was 55.4 years, 881 (49.6%) were males, 693 (51.3%) Doxorubicin were infected by HCV genotype 1, and 245 (13.8%) had cirrhosis at study entry. There were 1542 (86.7%) patients experienced SVR after receiving treatment. Higher platelet count, lower serum levels of total bilirubin, HCV RNA, and HCV genotype non-1 were independent predictors of achieving SVR. At the 5 years of post-treatment follow-up, there were 49 newly-diagnosed HCC cases (37 with SVR and 12 with non-SVR). The observed 5-year HCC risk was 2.1% for patients with SVR and 4.2% for those with non-SVR, respectively. The cumulative

risk of HCC was significantly higher for the non-SVR patients than the SVR patients (p<0.001). Patients with old ages, male gender, and low levels of hemoglobulin had an increased incidence of HCC. After adjustment for the potential confounders, the patients who

did not achieve SVR had 2.4 folds (95% confidence interval: 1.20-4.94) risk of developing HCC during the follow-up period. Conclusion: Chronic hepatitis C patients receiving peg-interferon plus ribavirin therapy who achieved SVR is associated with a substantial reduction of HCC risk. Patients with CHC infection should be encouraged to receive antiviral therapy. Disclosures: Yong Yuan – Employment: Bristol Myers Squibb Company Ming-Lung Yu – Advisory Committees or Review Panels: Roche, MSD, Abbott, Abbvie, Gilead; Grant/Research Support: Roche, MSD, Abbott, Abbvie; Speaking and Teaching: Roche, MSD, Abbott, find more Abbvie, Gilead Wan-Long Erlotinib Chuang – Advisory Committees or Review Panels: Gilead, Roche, Abbvie, MSD; Speaking and Teaching: BMS Gilbert J. L’Italien – Employment: bristol myers squibb; Stock Shareholder: bristol myers squibb The following people have nothing to disclose: Mei-Hsuan

Lee, Jia-Horng Kao, Chen-Hua Liu, Sheng-Nan Lu, I-Shyan Sheen, Hwai-I Yang, Chien-Jen Chen Background: Little information is available about early virologic responses for sofosbuvir (SOF)-based regimens in real-world populations with hepatitis C virus (HCV) infection. Methods: All patients starting a SOF-based regimen by 4/12/14 were identified in the VA HCV Clinical Case Registry. Exclusion criteria included: being on a HCV regimen to which SOF was added (n=41), baseline HCV RNA <1000 (n=25) and a non-standard SOF regimen (n=2). Standard regimens included: SOF+pegin-terferon+ribavirin (SPR), SOF+ribavirin (SR) and SOF+sime-previr±ribavirin (SS/R). We assessed 4 week HCV RNA using available results between 2 and 6 weeks after starting SOF in those who received at least 4 weeks of SOF. Advanced liver disease (ALD) was defined as FIB-4 >3.25. Univariate and multivariate analysis including baseline characteristics were performed for undetectable (UD) week 4 HCV RNA. Results: Of 731 patients starting SOF, 663 were included in the analyses.